A therapeutic combination of drugs for the treatment of a liver cancer includes safranal or a pharmaceutically acceptable pro-drug thereof, and sorafenib. In representative embodiments, the pro-drug is selected from the group of a safranal salt, hydrate, hemiacetal, acetal, thioacetal, silylether, tautomer, isomer, and combinations thereof. The safranal and the sorafenib may be compounded together in a same unitary pharmaceutical composition including both compounds. Alternatively, the safranal and the sorafenib may be provided in the form of separate pharmaceutical compositions.
